Tuberculin skin test and isoniazid prophylaxis among health care workers in high tuberculosis prevalence areas

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 1, 2011, Pages 14-23

  Khawcharoenporn, T ^a   Apisarnthanarak, Anucha ^a   Sungkanuparph, S ^b   Woeltje, K F ^c   Fraser, V J ^c  

^a THAMMASAT UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Health care workers; Isoniazid prophylaxis; Transmission; Tuberculin skin test; Tuberculosis

Indexed keywords

ISONIAZID;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; DISEASE TRANSMISSION; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; LATENT TUBERCULOSIS; OCCUPATIONAL HAZARD; OCCUPATIONAL HEALTH; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SKIN TEST; TUBERCULIN TEST; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; ATTITUDE OF HEALTH PERSONNEL; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HUMANS; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; ISONIAZID; LATENT TUBERCULOSIS; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; PATIENT ACCEPTANCE OF HEALTH CARE; PREDICTIVE VALUE OF TESTS; PREVALENCE; TUBERCULIN TEST;

EID: 78650119412     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Harries A D, Maher D, Nunn P. Practical and affordable measures for the protection of health care workers from tuberculosis in low-income countries. Bull World Health Organ 1997; 75: 477-489.
2. Barrett-Connor E. The epidemiology of tuberculosis in physicians. JAMA 1979; 241: 33-38.
3. Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. N Engl J Med 1995; 332: 92-98.
4. Jensen P A, Lambert L A, Iademarco M F, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care settings, 2005. MMWR Recomm Rep 2005; 54 (RR-17): 1-141.
5. World Health Organization. WHO policy on TB infection control in health care facilities, congregate settings and households. WHO/HTM/TB/2009.419. Geneva, Switzerland: WHO, 2009. http://whqlibdoc.who.int/publications/2009/ 9789241598323-eng.pdf Accessed October 2010.
6. LoBue P A, Catanzaro A. Effectiveness of a nosocomial tuberculosis control program at an urban teaching hospital. Chest 1998; 113: 1184-1189.
7. Wenger P N, Otten J, Breeden A, Orfas D, Beck-Sague C M, Jarvis W R. Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet 1995; 345: 235-240.
8. Yanai H, Limpakarnjanarat K, Uthaivoravit W, Mastro T D, Mori T, Tappero J W. Risk of Mycobacterium tuberculosis infection and disease among health care workers, Chiang Rai, Thailand. Int J Tuberc Lung Dis 2003; 7: 36-45.
9. Fridkin S K, Manangan L, Bolyard E, Jarvis W R. SHEA-CDC TB survey. Part II: Efficacy of TB infection control programs at member hospitals, 1992. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1995; 16: 135-140.
10. Roy M C, Fredrickson M, Good N L, Hunter S A, Nettleman M D. Correlation between frequency of tuberculosis and compliance with control strategies. Infect Control Hosp Epidemiol 1997; 18: 28-31.
11. Roth V R, Garrett D O, Laserson K F, et al. A multicenter evaluation of tuberculin skin test positivity and conversion among health care workers in Brazilian hospitals. Int J Tuberc Lung Dis 2005; 9: 1335-1342.
12. Bonifacio N, Saito M, Gilman R H, et al. High risk for tuberculosis in hospital physicians, Peru. Emerg Infect Dis 2002; 8: 747-748.
13. Centers for Disease Control and Prevention. Mycobacterium tuberculosis transmission in a newborn nursery and maternity ward - New York City, 2003. MMWR 2005; 54: 1280-1283.
14. Froeschle J E, Ruben F L, Bloh A M. Immediate hypersensitivity reactions after use of tuberculin skin testing. Clin Infect Dis 2002; 34: e12-e13.
15. Smieja M J, Marchetti C A, Cook D J, Smaill F M. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; (2): CD001363.
16. Jasmer R M, Nahid P, Hopewell P C. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002; 347: 1860-1866.
17. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 2005; 26: 465-473.
18. Salpeter S R, Salpeter E E. Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 2004; 25: 1056-1061.
19. Khan K, Muennig P, Behta M, Zivin J G. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347: 1850-1859.
20. Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992; 70: 149-159.
21. Khawcharoenporn T, Apisarnthanarak A, Thongphubeth K, Yuekyen C, Mundy L M. Tuberculin skin tests among medical students with prior bacilli Calmette-Guérin vaccination in a setting with a high prevalence of tuberculosis. Infect Control Hosp Epidemiol 2009; 30: 705-709.
22. Tissot F, Zanetti G, Francioli P, Zellweger J P, Zysset F. Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size? Clin Infect Dis 2005; 40: 211-217.
23. von Reyn C F, Horsburgh C R, Olivier K N, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001; 5: 1122-1128.
24. Blumberg H M, Leonard M K Jr, Jasmer R M. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293: 2776-2784.
25. Mazurek G H, Jereb J, Lobue P, Iademarco M F, Metchock B, Vernon A; Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the Quanti-FERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54(RR-15): 49-55.
26. National Institute for Health and Clinical Excellence. NICE clinical guideline 33. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: NICE, 2006. http://guidance.nice.org. uk/CG33/Guidance/pdf/English Accessed October 2010.
27. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354.
28. Mazurek G H, LoBue P A, Daley C L, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747.
29. Nienhaus A, Schablon A, Diel R. Interferon-gamma release assay for the diagnosis of latent TB infection-analysis of discordant results, when compared to the tuberculin skin test. PLoS One 2008; 3: e2665.
30. Brodie D, Lederer D J, Gallardo J S, Trivedi S H, Burzynski J N, Schluger N W. Use of an interferon-gamma release assay to diagnose latent tuberculosis infection in foreign-born patients. Chest 2008; 133: 869-874.
31. Kang Y A, Lee H W, Yoon H I, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293: 2756-2761.
32. Eum S Y, Lee Y J, Kwak H K, et al. Evaluation of the diagnostic utility of a whole-blood interferon-gamma assay for determining the risk of exposure to Mycobacterium tuberculosis in bacille Calmette-Guerin (BCG)-vaccinated individuals. Diagn Microbiol Infect Dis 2008; 61: 181-186.
33. Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respir Med 2009; 103: 1838-1853.
34. Kowada A, Takahashi O, Shimbo T, Ohde S, Tokuda Y, Fukui T. Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 2008; 12: 235-251.
35. Marra F, Marra C A, Sadatsafavi M, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 2008; 12: 1414-1424.
36. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a costeffectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26.
37. Alvarez-León E E, Espinosa-Vega E, Santana-Rodríguez E, et al. Screening for tuberculosis infection in Spanish healthcare workers: comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test. Infect Control Hosp Epidemiol 2009; 30: 876-883.
38. Carvalho A C, Crotti N, Crippa M, et al. QuantiFERON-TB Gold test for healthcare workers. J Hosp Infect 2008; 69: 91-92.
39. Fox B D, Kramer M R, Mor Z, et al. The QuantiFERON®-TB Gold assay for tuberculosis screening in healthcare workers: a cost-comparison analysis. Lung 2009; 187: 413-419.
40. Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese health care workers. Infect Control Hosp Epidemiol 2006; 27: 442-448.
41. Hotta K, Ogura T, Nishii K, et al. Whole blood interferongamma assay for baseline tuberculosis screening among Japanese healthcare students. PLoS One 2007; 2: e803.
42. Kobashi Y, Mouri K, Yagi S, et al. Usefulness of the Quanti-FERON TB-2G test for the differential diagnosis of pulmonary tuberculosis. Intern Med 2008; 47: 237-243.
43. Lee S S, Liu Y C, Huang T S, et al. Comparison of the interferon-gamma release assay and the tuberculin skin test for contact investigation of tuberculosis in BCG-vaccinated health care workers. Scand J Infect Dis 2008; 40: 373-380.
44. Mirtskhulava V, Kempker R, Shields K L, et al. Prevalence and risk factors for latent tuberculosis infection among health care workers in Georgia. Int J Tuberc Lung Dis 2008; 12: 513-519.
45. Nienhaus A, Schablon A, Bâcle C L, Siano B, Diel R. Evaluation of the interferon-gamma release assay in healthcare workers. Int Arch Occup Environ Health 2008; 81: 295-300.
46. Pai M, Gokhale K, Joshi R, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 2005; 293: 2746-2755.
47. Soborg B, Andersen A B, Larsen H K, et al. Detecting a low prevalence of latent tuberculosis among health care workers in Denmark detected by M. tuberculosis specific IFN-gamma whole-blood test. Scand J Infect Dis 2007; 39: 554-559.
48. Barsegian V, Mathias K D, Wrighton-Smith P, Grosse-Wilde H, Lindemann M. Prevalence of latent tuberculosis infection in German radiologists. J Hosp Infect 2008; 69: 69-76.
49. Chee C B, Lim L K, Barkham T M, et al. Use of a T-cell interferon-gamma release assay to evaluate tuberculosis risk in newly qualified physicians in Singapore healthcare institutions. Infect Control Hosp Epidemiol 2009; 30: 870-875.
50. Girardi E, Angeletti C, Puro V, et al. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among health care workers. Euro Surveill 2009; 14: pii: 19373.
51. Menzies R, Vissandjee B. Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992; 145: 621-625.
52. Pollock N R, Campos-Neto A, Kashino S, et al. Discordant QuantiFERON-TB Gold test results among US healthcare workers with increased risk of latent tuberculosis infection: a problem or solution? Infect Control Hosp Epidemiol 2008; 29: 878-886.
53. de Perio M A, Tsevat J, Roselle G A, Kralovic S M, Eckman M H. Cost-effectiveness of interferon-gamma release assays vs. tuberculin skin tests in health care workers. Arch Intern Med 2009; 169: 179-187.
54. Camins B C, Bock N, Watkins D L, Blumberg H M. Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion. JAMA 1996; 275: 1013-1015.
55. Sahni R, Miranda C, Yen-Lieberman B, et al. Does the implementation of an interferon-gamma release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers? Infect Control Hosp Epidemiol 2009; 30: 197-199.
56. Nolan C M, Goldberg S V, Buskin S E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
57. Padmapriyadarsini C, Swaminathan S. Preventive therapy for tuberculosis in HIV infected individuals. Indian J Med Res 2005; 121: 415-423. (Pubitemid 40691374)
58. Cattamanchi A, Dantes R B, Metcalfe J Z, et al. Clinical characteristics and treatment outcomes of patients with isoniazidmonoresistant tuberculosis. Clin Infect Dis 2009; 48: 179-185.
59. Fairshter R D, Randazzo G P, Garlin J, Wilson A F. Failure of isoniazid prophylaxis after exposure to isoniazid-resistant tuberculosis. Am Rev Respir Dis 1975; 112: 37-42.
60. Karchmer T B, Phipps J D, Giannetta E T, Farr B M. Isoniazid-resistant cavitary tuberculosis in a physician following isoniazid prophylaxis. Infect Control Hosp Epidemiol 2002; 23: 622-625.
61. Apisarnthanarak A, Thongphubeth K, Yuekyen C, Mundy L M. Postexposure detection of Mycobacterium tuberculosis infection in health care workers in resource-limited settings. Clin Infect Dis 2008; 47: 982-984.
62. Munseri P J, Talbot E A, Mtei L, Fordham von Reyn C. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 2008; 12: 1037-1041.
63. LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009; 22: 167-173.
64. Fraser A, Paul M, Attamna A, Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006; 10: 19-23.
65. Centers for Disease Control and Prevention. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992; 41(RR-11): 61-71.
66. Schaaf H S, Gie R P, Kennedy M, Beyers N, Hesseling P B, Donald P R. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109: 765-771.
67. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to anti-tuberculosis drugs. World Health Organization-International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 2001; 344: 1294-1303.
68. Page K R, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs. isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-1870.
69. Cook P P, Maldonado R A, Yarnell C T, Holbert D. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. Clin Infect Dis 2006; 43: 271-275.
70. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
71. Ziakas P D, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49: 1883-1889.
72. Holland D P, Sanders G D, Hamilton C D, Stout J E. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009; 179: 1055-1060.
73. Gao X F, Wang L, Liu G J, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006; 10: 1080-1090.
74. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs. isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123: 102-106.
75. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States, 2001. MMWR 2001; 50: 733-735.
76. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40: 670-676.
77. Kritski A L, Marques M J, Rabahi M F, et al. Transmission of tuberculosis to close contacts of patients with multidrugresistant tuberculosis. Am J Respir Crit Care Med 1996; 153: 331-335.
78. Menzies D, Dion M J, Francis D, et al. In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection. Int J Tuberc Lung Dis 2005; 9: 1343-1348.
79. Shukla S J, Warren D K, Woeltje K F, Gruber C A, Fraser V J. Factors associated with the treatment of latent tuberculosis infection among health-care workers at a midwestern teaching hospital. Chest 2002; 122: 1609-1614.
80. Kwara A, Herold J S, Machan J T, Carter E J. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 2008; 133: 862-868.
81. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006; 174: 349-355.
82. Pollock N R, Kashino S S, Napolitano D R, et al. Evaluation of the effect of treatment of latent tuberculosis infection on Quanti-FERON-TB gold assay results. Infect Control Hosp Epidemiol 2009; 30: 392-395.